Table 3 Risk of cognitive impairment according to KOLT by APOE4 status.

			OR* of cognitive impairment† (95% CI)
	Impaired (n)	Unimpaired (n)
			Unadjusted	Adjusted‡
Women
APOE4 negatives	72	749	Reference	Reference
APOE4 heterozygotes	44	294	1.6 (1.05 to 2.3)	1.8 (1.1 to 2.8)
APOE4 homozygotes	5	33	1.6 (0.6 to 4.2)	1.1 (0.3 to 3.7)
Men
APOE4 negatives	51	609	Reference	Reference
APOE4 heterozygotes	28	265	1.3 (0.8 to 2.0)	1.1 (0.6 to 2.1)
APOE4 homozygotes	14	17	9.8 (4.6 to 21)	10.7 (4.7 to 24)

APOE4, apolipoprotein E ε4 allele; CI, confidence interval; KOLT, Kendrick Objective Learning Test; OR, odds ratio.

*Compared with participants without APOE4.

†Lowest decile by sex.

‡For the covariates listed in the Methods section, of which the following remained in each regression: women, APOE4 heterozygotes: education, high‐density lipoprotein cholesterol, triglycerides, history of cardiovascular disease or hypertension; women, APOE4 homozygotes: history of cardiovascular disease or hypertension; men, APOE4 heterozygotes: education, systolic blood pressure, creatinine, history of cardiovascular disease or hypertension; men, APOE4 homozygotes: education.